| 13.04 0.21 (1.64%) | 08-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.95 | 1-year : | 18.63 |
| Resists | First : | 13.65 | Second : | 15.95 |
| Pivot price | 11.69 |
|||
| Supports | First : | 11.28 | Second : | 9.81 |
| MAs | MA(5) : | 12.81 |
MA(20) : | 11.35 |
| MA(100) : | 10.82 |
MA(250) : | 13.84 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 78.2 |
D(3) : | 76.8 |
| RSI | RSI(14): 67.3 |
|||
| 52-week | High : | 23.17 | Low : | 8.99 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PRGO ] has closed below upper band by 22.9%. Bollinger Bands are 161% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 13.07 - 13.12 | 13.12 - 13.18 |
| Low: | 12.48 - 12.54 | 12.54 - 12.59 |
| Close: | 12.95 - 13.04 | 13.04 - 13.13 |
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Thu, 13 Aug 2026
Perrigo: The Rebound Is Just Getting Started (NYSE:PRGO) - Seeking Alpha
Wed, 12 Aug 2026
Perrigo (NYSE:PRGO) Stock Price Down 4.4% - Should You Sell? - MarketBeat
Wed, 12 Aug 2026
PRGO: Structural improvements and a diversified portfolio drive growth in a resilient healthcare market - TradingView
Tue, 11 Aug 2026
Sei Investments Co. Sells 121,359 Shares of Perrigo Company plc $PRGO - MarketBeat
Mon, 10 Aug 2026
Are Investors Undervaluing Perrigo (PRGO) Right Now? - finance.yahoo.com
Sat, 08 Aug 2026
Results: Perrigo Company plc Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 138 (M) |
| Shares Float | 138 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 120.7 (%) |
| Shares Short | 22,930 (K) |
| Shares Short P.Month | 17,580 (K) |
| EPS | -12.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.09 |
| Profit Margin | -41.9 % |
| Operating Margin | 3.8 % |
| Return on Assets (ttm) | 1.9 % |
| Return on Equity (ttm) | -48.8 % |
| Qtrly Rev. Growth | -3.3 % |
| Gross Profit (p.s.) | 9.97 |
| Sales Per Share | 29.91 |
| EBITDA (p.s.) | 4.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 196 (M) |
| Levered Free Cash Flow | 437 (M) |
| PE Ratio | -1.07 |
| PEG Ratio | 1.1 |
| Price to Book value | 0.72 |
| Price to Sales | 0.43 |
| Price to Cash Flow | 9.2 |
| Dividend | 0.28 |
| Forward Dividend | 0 |
| Dividend Yield | 2.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|